Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Upadacitinib Plus Topical Corticosteroids in Moderate to Severe Atopic Dermatitis
2017-005126-37Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of upadacitinib in atopic dermatitis (AD), sponsored by AbbVie Inc.. Started Aug 2018; status: active.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2017-005126-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005126-37.